OHB's €510m Share Dilution Casts a Shadow That Even a Billion-Euro Contract Can't Lift

OHB's €510M capital raise and shareholder exodus overshadow its €1B SES satellite contract, sending shares down 30% in a month.

The arithmetic at OHB SE has become brutally simple for shareholders: a €510 million capital raise that expanded the free float from roughly 6 percent to as much as 26 percent has overwhelmed the company's most significant commercial victory in years. When Bremen-based OHB announced on Tuesday that it had secured a contract worth close to €1 billion from SES S.A. to build 18 satellite platforms for Europe's IRIS² security programme, the stock did what it has done all summer — it fell.

The disconnect between operational achievement and market reception could hardly be starker. The SES order, which forms part of the EU Commission-mandated SpaceRISE consortium alongside Eutelsat and Hispasat, involves platforms weighing approximately 2.6 tonnes each and delivering around 15 kilowatts of power. First launches are pencilled in for 2029, with data transmission slated to begin the following year. Yet investors responded by sending the shares down 2.9 percent on Wednesday to close at €177.60, extending the weekly decline to 5.9 percent and the 30-day slide to a painful 30 percent.

A Shareholder Exodus That Reshaped the Register

The root cause of the malaise lies in a June restructuring of the shareholder base rather than any deterioration in the underlying business. On 22 June, the board, with supervisory board approval, resolved a rights issue of up to 1,702,480 new shares — equivalent to 8.86 percent of share capital — priced at €300 apiece. The Fuchs family vehicles FFS, VOLPAIA and Martello Value, along with KKR-affiliated Orchid Lux, waived their subscription rights, paving the way for the free float to balloon from around 6 percent to as much as 26 percent.

The market's initial reaction came even before the mechanics were complete. The announcement on 15 June triggered an immediate discount of roughly 10 percent. When the first tranche of just over 1.6 million new shares began trading on 26 June, Orchid Lux simultaneously placed a substantial portion of its approximately 29 percent stake through an upsized bookbuilding at the same €300 price. By early July, OHB confirmed the second tranche had also been completed, with net proceeds earmarked for production expansion, strategic acquisitions, launch vehicles and future programmes.

The departure of a major anchor shareholder, combined with the dilution effect of a significantly enlarged share count, has proven a toxic cocktail for the stock price. Since the capital increase, the shares have lost more than half their value; since OHB's promotion to the SDAX index just over three weeks ago, they have shed almost a third.

Technical Damage Compounds the Pressure

Chart-based investors have found little comfort in recent sessions. The stock currently trades about a quarter below its 50-day moving average of €243.21 and roughly three-tenths beneath the 200-day average of €258.40 — a configuration that confirms a multi-month downtrend. The relative strength index stands at 33.3, signalling oversold conditions, though no sustainable rebound has yet materialised. The secondary article's slightly different 50-day reference of €245.91 reflects the rapidly shifting average as prices have fallen.

Thursday brought some respite, with the shares climbing 2.4 percent from Wednesday's close to €181.80. But the 30-day volatility reading of 76 percent annualised tells its own story: this remains a stock that moves violently in both directions, and the prevailing bias has been firmly downward.

A Defining Test Arrives in November

The analyst community has begun to push back against the pessimism. Oddo BHF initiated coverage roughly a week ago with an "Outperform" rating and a price target of €290 — a level that implies substantial upside from current trading, though it sits notably below the €300 placement price from June. The brokerage's optimism appears anchored in the IRIS² contract and the growth trajectory it implies for European satellite manufacturing.

Whether that confidence is justified will face its next major test on 12 November, when OHB publishes third-quarter figures. The numbers will need to demonstrate that the SES order can translate into genuine earnings momentum — and, perhaps just as importantly, that the market's fixation on the company's new share structure begins to fade. Until then, the fundamental story and the technical reality remain stubbornly out of sync, leaving investors to weigh a transformed register against a transformed order book.